We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
Read MoreHide Full Article
On Sep 20, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) , a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio.
Shares of the company have outperformed its industry over the past year. The stock has declined 13.6%, narrower than the industry's decrease of 24.6%.
Illumina consistently showcases robust performance across a broad range of sequencing applications. The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter of 2019 also buoy optimism. Meanwhile, the HiSeq to NovaSeq upgrade cycle is progressing well and the NextSeq placements are strong as well. Moreover, we are looking forward to the company's newly-inked Pacific Biosciences deal.
In the last reported quarter, the company saw a solid uptick in oncology testing on the application of genomic information. It is upbeat about 12 new drugs being introduced with a predictive biomarker (nine of which were approved for oncology indications). In 2019, we expect Illumina to progress within this space as a powerful provider of genomic testing.
In the quarter, EMEA demonstrated impressive growth of 7% with a record number of sequencing systems and sequencing consumables delivered. Despite revenues from Greater China falling 9% year over year during the period, there are currently 3-4 million NIPT tests done annually in the country.
On the flip side, HiSeq consumables persistently drop as expected. Seasonality in direct-to-consumer (DTC) functionality also continues to erode Illumina’s microarray sales. Contraction in both margins and a year-over-year deterioration in Service and Other revenues are concerns. Additionally, the company is operating in a tough competitive landscape.
Haemonetics’ long-term earnings growth rate is expected to be 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Amedisys’ long-term earnings growth rate is expected to be 16.26%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
On Sep 20, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) , a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio.
Shares of the company have outperformed its industry over the past year. The stock has declined 13.6%, narrower than the industry's decrease of 24.6%.
Illumina consistently showcases robust performance across a broad range of sequencing applications. The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter of 2019 also buoy optimism. Meanwhile, the HiSeq to NovaSeq upgrade cycle is progressing well and the NextSeq placements are strong as well. Moreover, we are looking forward to the company's newly-inked Pacific Biosciences deal.
Illumina, Inc. Price
Illumina, Inc. price | Illumina, Inc. Quote
In the last reported quarter, the company saw a solid uptick in oncology testing on the application of genomic information. It is upbeat about 12 new drugs being introduced with a predictive biomarker (nine of which were approved for oncology indications). In 2019, we expect Illumina to progress within this space as a powerful provider of genomic testing.
In the quarter, EMEA demonstrated impressive growth of 7% with a record number of sequencing systems and sequencing consumables delivered. Despite revenues from Greater China falling 9% year over year during the period, there are currently 3-4 million NIPT tests done annually in the country.
On the flip side, HiSeq consumables persistently drop as expected. Seasonality in direct-to-consumer (DTC) functionality also continues to erode Illumina’s microarray sales. Contraction in both margins and a year-over-year deterioration in Service and Other revenues are concerns. Additionally, the company is operating in a tough competitive landscape.
Stocks Worth a Look
A few better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Baxter (BAX - Free Report) and Amedisys (AMED - Free Report) , each carrying a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Haemonetics’ long-term earnings growth rate is expected to be 7.13%.
Baxter’s long-term earnings growth rate is projected at 12.8%.
Amedisys’ long-term earnings growth rate is expected to be 16.26%.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>